PortViewPortView
HilleVax logo

HilleVax (HLVX) Stock Analysis

NASDAQHealthcareBiotechnology

$2.09-0.48%
1-year price historyRange $1.39 – $2.17
52-week range$2.09
$1.34$2.17

What HilleVax does

HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.

Key metrics

Market cap
$104.76M
P/E (TTM)
-1.45
EPS (TTM)
$-1.44
Beta
0.77
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$2.09
200-day avg
$1.92
52-week high
$2.17
52-week low
$1.34
CEO
Robert M. Hershberg

ETFs linked to HLVX

Broad-market and Healthcare sector ETFs an investor holding HilleVax is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HLVX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze HLVX in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for HilleVax?
HilleVax trades under the ticker HLVX on NASDAQ.
Which exchange is HLVX listed on?
HLVX is listed on NASDAQ.
What sector does HilleVax operate in?
HilleVax is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze HLVX in a portfolio?
PortView shows HLVX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.